Lumican is increased in experimental and clinical heart failure, and its production by cardiac fibroblasts is induced by mechanical and proinflammatory stimuli
Version of Record online: 2 APR 2013
© 2013 The Authors Journal compilation © 2013 FEBS
The FEBS Journal
Special Issue: Proteoglycans: signaling, targeting and therapeutics
Volume 280, Issue 10, pages 2382–2398, May 2013
How to Cite
Engebretsen, K. V. T., Lunde, I. G., Strand, M. E., Waehre, A., Sjaastad, I., Marstein, H. S., Skrbic, B., Dahl, C. P., Askevold, E. T., Christensen, G., Bjørnstad, J. L. and Tønnessen, T. (2013), Lumican is increased in experimental and clinical heart failure, and its production by cardiac fibroblasts is induced by mechanical and proinflammatory stimuli. The FEBS Journal, 280: 2382–2398. doi: 10.1111/febs.12235
- Issue online: 9 MAY 2013
- Version of Record online: 2 APR 2013
- Accepted manuscript online: 10 MAR 2013 07:43AM EST
- Manuscript Accepted: 5 MAR 2013
- Manuscript Revised: 14 FEB 2013
- Manuscript Received: 29 NOV 2012
Fig. S1. Increased cardiac lumican mRNA 16 weeks following AB.
Fig. S2. Increased fibromodulin, decorin and biglycan in LV biopsies from patients with end-stage heart failure.
Fig. S3. Illustrations of western blots probed with antilumican.
Table S1. Gene probes used for qPCR.
Table S2. Antibodies used for western blot.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.